Delayed
Hong Kong S.E.
04:08:06 2024-04-30 EDT
|
5-day change
|
1st Jan Change
|
11.6
HKD
|
+0.52%
|
|
+8.21%
|
-6.90%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,668
|
6,375
|
9,084
|
8,198
|
8,673
|
7,534
|
-
|
-
|
Enterprise Value (EV)
1 |
5,204
|
5,685
|
7,349
|
7,241
|
8,673
|
7,534
|
7,534
|
7,534
|
P/E ratio
|
24
x
|
22.5
x
|
13.3
x
|
17.6
x
|
15.7
x
|
11.8
x
|
9.25
x
|
7.25
x
|
Yield
|
0.18%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.63
x
|
6.8
x
|
8.2
x
|
6.82
x
|
7.18
x
|
5.03
x
|
3.95
x
|
3.16
x
|
EV / Revenue
|
6.63
x
|
6.8
x
|
8.2
x
|
6.82
x
|
7.18
x
|
5.03
x
|
3.95
x
|
3.16
x
|
EV / EBITDA
|
20.3
x
|
18.5
x
|
23.6
x
|
23
x
|
25.6
x
|
19.7
x
|
15.4
x
|
12.1
x
|
EV / FCF
|
57.2
x
|
-
|
-
|
-
|
18.1
x
|
66.1
x
|
23
x
|
16.2
x
|
FCF Yield
|
1.75%
|
-
|
-
|
-
|
5.52%
|
1.51%
|
4.34%
|
6.19%
|
Price to Book
|
7.03
x
|
5.91
x
|
1.92
x
|
1.99
x
|
1.51
x
|
1.28
x
|
1.12
x
|
0.97
x
|
Nbr of stocks (in thousands)
|
345,852
|
345,852
|
384,280
|
383,569
|
383,569
|
383,568
|
-
|
-
|
Reference price
2 |
16.39
|
18.43
|
12.34
|
14.10
|
11.32
|
10.74
|
10.74
|
10.74
|
Announcement Date
|
20-03-16
|
21-03-29
|
22-02-24
|
23-02-27
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
855.3
|
937.7
|
1,108
|
1,202
|
1,209
|
1,497
|
1,906
|
2,382
|
EBITDA
1 |
279.9
|
345.3
|
384.4
|
357.2
|
339.2
|
383
|
488.9
|
624.5
|
EBIT
1 |
273.5
|
330.1
|
367.6
|
-
|
306
|
370.6
|
474.2
|
603.7
|
Operating Margin
|
31.98%
|
35.2%
|
33.17%
|
-
|
25.32%
|
24.76%
|
24.87%
|
25.35%
|
Earnings before Tax (EBT)
1 |
273
|
329.8
|
367.4
|
336.9
|
305.9
|
370.1
|
473.7
|
603.6
|
Net income
1 |
236.8
|
283.4
|
322.4
|
307.7
|
277.8
|
336
|
429.8
|
547
|
Net margin
|
27.68%
|
30.22%
|
29.09%
|
25.61%
|
22.99%
|
22.45%
|
22.54%
|
22.97%
|
EPS
2 |
0.6840
|
0.8200
|
0.9300
|
0.8000
|
0.7200
|
0.9100
|
1.160
|
1.480
|
Free Cash Flow
1 |
99.13
|
-
|
-
|
-
|
478.5
|
114
|
327
|
466
|
FCF margin
|
11.59%
|
-
|
-
|
-
|
39.59%
|
7.62%
|
17.15%
|
19.57%
|
FCF Conversion (EBITDA)
|
35.41%
|
-
|
-
|
-
|
141.05%
|
29.77%
|
66.89%
|
74.62%
|
FCF Conversion (Net income)
|
41.87%
|
-
|
-
|
-
|
172.22%
|
33.93%
|
76.09%
|
85.19%
|
Dividend per Share
|
0.0300
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-16
|
21-03-29
|
22-02-24
|
23-02-27
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2023 S1
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
1 |
0.3300
|
Dividend per Share
|
-
|
Announcement Date
|
23-08-30
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
464
|
690
|
1,735
|
957
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
99.1
|
-
|
-
|
-
|
478
|
114
|
327
|
466
|
ROE (net income / shareholders' equity)
|
33%
|
30.1%
|
18.2%
|
11.9%
|
9.93%
|
10.7%
|
12.3%
|
14%
|
ROA (Net income/ Total Assets)
|
23.4%
|
20.6%
|
14.2%
|
9.6%
|
7.61%
|
-
|
-
|
-
|
Assets
1 |
1,012
|
1,378
|
2,271
|
3,205
|
3,650
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.330
|
3.120
|
6.430
|
7.080
|
7.500
|
8.410
|
9.570
|
11.00
|
Cash Flow per Share
2 |
1.670
|
0.7500
|
0.5100
|
0.1100
|
1.330
|
0.7100
|
0.7400
|
0.9900
|
Capex
1 |
132
|
23.9
|
199
|
24.8
|
33.2
|
41.2
|
52.1
|
53.9
|
Capex / Sales
|
15.48%
|
2.55%
|
17.99%
|
2.07%
|
2.75%
|
2.75%
|
2.73%
|
2.26%
|
Announcement Date
|
20-03-16
|
21-03-29
|
22-02-24
|
23-02-27
|
24-02-28
|
-
|
-
|
-
|
Last Close Price
10.74
CNY Average target price
21.26
CNY Spread / Average Target +98.09% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.90% | 1.05B | | +12.37% | 129B | | -9.23% | 10.77B | | +2.17% | 9.05B | | +18.79% | 7.38B | | +20.77% | 4.88B | | +6.97% | 3.41B | | -1.41% | 3.07B | | -5.07% | 2.24B | | -4.22% | 2.12B |
Medical Devices & Implants
|